Fulcrum Therapeutics (FULC) Accounts Payables (2019 - 2025)
Historic Accounts Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $2.9 million.
- Fulcrum Therapeutics' Accounts Payables fell 2932.44% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 2932.44%. This contributed to the annual value of $1.2 million for FY2024, which is 5778.02% down from last year.
- Fulcrum Therapeutics' Accounts Payables amounted to $2.9 million in Q3 2025, which was down 2932.44% from $1.8 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Accounts Payables ranged from a high of $6.0 million in Q1 2022 and a low of $1.2 million during Q4 2024
- Over the past 5 years, Fulcrum Therapeutics' median Accounts Payables value was $3.7 million (recorded in 2021), while the average stood at $3.6 million.
- Per our database at Business Quant, Fulcrum Therapeutics' Accounts Payables skyrocketed by 3101.17% in 2023 and then crashed by 6092.82% in 2025.
- Fulcrum Therapeutics' Accounts Payables (Quarter) stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then plummeted by 57.78% to $1.2 million in 2024, then surged by 145.36% to $2.9 million in 2025.
- Its last three reported values are $2.9 million in Q3 2025, $1.8 million for Q2 2025, and $1.5 million during Q1 2025.